JMIR Cardio - Search

View query in Help articles search

Field

e.g. mhealth

Operator

Field

Criteria

e.g. John Smith or 0000-0001-6479-5330

Exact Match for Criteria

Yes No

Search Results (1 to 2 of 2 Results)

Download search results: CSV END BibTex RIS

Sort by:

Use of Digital Technology Tools to Characterize Adherence to Prescription-Grade Omega-3 Polyunsaturated Fatty Acid Therapy in Postmyocardial or Hypertriglyceridemic Patients in the DIAPAsOn Study: Prospective Observational Study

Omega-3-acid ethyl esters (OM3 EE) are available as a prescription-only medication (Omacor, Abbott Laboratories Gmb H) that is a preparation of highly purified long-chain omega-3 polyunsaturated fatty acids (n-3 PUFAs) (eicosapentaenoic acid/docosahexaenoic acid in a 1.2:1 ratio and 90% purity); this medication is widely approved for use at a daily dose of 1 g for the secondary prevention of major cardiovascular events in patients who have survived an MI, or at doses of 2 to 4 g/day for the regulation of triglyceride

Gregory P Arutyunov, Alexander G Arutyunov, Fail T Ageev, Tatiana V Fofanova

JMIR Cardio 2022;6(2):e37490

Download Citation: END BibTex RIS

Download PDF Download XML

Digital Technology Tools to Examine Patient Adherence to a Prescription-Only Omega-3 Polyunsaturated Fatty Acid Therapy To Mitigate Cardiovascular Risk: Protocol for a Prospective Observational Study and Preliminary Demographic Analysis

One such prescription n-3 polyunsaturated fat preparation (OMACOR, Market Authorization Holder Abbott Laboratories Gmb H), is available in Russia as 1 g capsules containing 840 mg of ethyl esters of omega-3 fatty acids—a 1.2 to 1 ratio (eicosapentaenoic acid to docosahexanoic acid, 90% purity)—and 160 mg of excipients.

Gregory P Arutyunov, Alexander G Arutyunov, Fail T Ageev, Tatiana V Fofanova

JMIR Res Protoc 2021;10(8):e29061

Download Citation: END BibTex RIS

Download PDF Download XML

Search Articles

Search Results (1 to 2 of 2 Results)